|
KMID : 1141720210090010025
|
|
폐쇄성폐질환
2021 Volume.9 No. 1 p.25 ~ p.32
|
|
|
ICS Usage in Real Practice and Appropriate Treatment
|
|
Moon Ji-Yong
|
|
|
Abstract
|
|
|
|
Recently, limited use of Inhaled corticosteroid (ICS) in COPD patients is recommended. In the treatment of COPD, ICS was shown to be effective in improving pulmonary function and reducing frequency of acute exacerbation but increased the risk of pneumonia. Several studies presented that ICS is effective in preventing acute exacerbation, but the effectiveness was depending on the level of the patient’s blood eosinophil count and history of asthma. In the Korean COPD guideline, it was recommended to add ICS to the bronchodilator when patients develop acute exacerbation despite LAMA/LABA treatment, have a history of asthma, or have high blood eosinophil counts. To conclude, patients with a history of asthma and currently using ICS to treat COPD are not recommended to withdrawal ICS. Withdrawal of ICS is recommended if the patient has no history of asthma and no previous exacerbation in one year.
|
|
|
KEYWORD
|
|
|
COPD, Inhaled corticosteroid, Acute exacerbation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|